tti-622
pfizer
['dlbcl', 'lymphoma', 'tti-622', 'tti,622,01']
dr. krish patel presents on ongoing research at #asco22: tti-622-01: a phase 1a/1b dose-escalation and expansion trial of tti-622 in patients with advanced hematologic malignancies, including diffuse large b-cell lymphoma (dlbcl). 
Sharing #Cancer #Research news updates from @Swedish Cancer Institute. Personalized medicine. Leading research.

Tweets do not constitute medical advice